Buckle up for $1, page-16

I believe you are referring to AnteoTech (ASX company that "...has developed a proof of concept COVID-19 and flu multiplex test platform" for antigen testing. Yes, you are right its past proof of concept for this type of testing and looking to commercialise with partners.

The problem seems to be that current antigen results show 5%-30% error factor depending on test type; needs enough Covid19 viral protein material and sometimes not enough is gathered/produced/depends on disease stage). AnteoTech's proof of concept seems to indicate 20% error improvement on this (which would be great competition in antigen test space, sure!).

AnteoTech's improved test though is still months away from approval & production stages (commercialise, further wider tests, validate results, submit for health body approvals, scale up manufacturing, signing contracts etc) so I don't think in terms of potential market share one can compare yet!

Am not arguing which type of antibody/antigen test kit would be more effective here - we already that chat earlier